References
- Rose MR; ENMC IBM Working Group. 188th ENMC international workshop: inclusion body myositis, 2–4 December 2011, Naarden, The Netherlands. Neuromuscul Disord 2013;23:1044–55.
- Pluk H, van Hoeve BJ, van Dooren SH, Stammen-Vogelzangs J, van der Heijden A, Schelhaas HJ, et al. Autoantibodies to cytosolic 5ʹ-nucleotidase 1A in inclusion body myositis. Ann Neurol 2013;73:397–407.
- Greenberg SA. Cytoplasmic 5ʹ-nucleotidase autoantibodies in inclusion body myositis: isotypes and diagnostic utility. Muscle Nerve 2014;50:488–92.
- Brady S, Squier W, Sewry C, Hanna M, Hilton-Jones D, Holton JL. A retrospective cohort study identifying the principal pathological features useful in the diagnosis of inclusion body myositis. BMJ Open 2014;4:e004552.
- Herbert MK, Stammen-Vogelzangs J, Verbeek MM, Rietveld A, Lundberg IE, Chinoy H, et al. Disease specificity of autoantibodies to cytosolic 5ʹ-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. Ann Rheum Dis 2016;75:696–701.
- Dimachkie MM, Barohn RJ. Inclusion body myositis. Semin Neurol 2012;32:237–45.